NCT00298298View on ClinicalTrials.gov

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Non-Small Cell Lung Cancer - Completely Resectable
Interventions
BIOLOGICAL

L-Vax: Autologous, DNP-Modified NSCLC Vaccine

autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months

Trial Locations (2)

19104

University of Pennsylvania Cancer Center, Philadelphia

72703

Highlands Oncology Group, Fayetteville

Sponsors

Lead Sponsor

AVAX Technologies
All Listed Sponsors
lead

AVAX Technologies

INDUSTRY

NCT00298298 - DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter